Skip Navigation


Carcinogenesis Advance Access originally published online on November 21, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/3/375    most recent
bgh019v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lindahl, T.
Right arrow Articles by Bergh, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindahl, T.
Right arrow Articles by Bergh, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 25, No. 3, 375-380, March 2004
Carcinogenesis vol.25 no.3 © Oxford University Press 2004; all rights reserved.

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer

Thomas Lindahl5, Göran Landberg1, Johan Ahlgren2, Hans Nordgren3, Torbjörn Norberg, Sigrid Klaar, Lars Holmberg4 and Jonas Bergh

Department of Oncology and Pathology, Radiumhemmet, Karolinska Hospital and Institute R8:03, S-171 76 Stockholm, Sweden, 1 Division of Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden, 2 Department of Oncology, Uppsala University–Gävle County Hospital, Gävle, Sweden, 3 Department of Pathology, Uppsala University Hospital, Uppsala, Sweden and 4 Uppsala-Örebro Regional Oncologic Center, Uppsala, Sweden

Cyclin E is one of the key regulators of the G1/S transition in the cell cycle. Overexpression of cyclin E has been observed in several malignancies and is associated with high proliferation, aberrant expression of other cell cycle regulators and chromosomal instability in vitro. To explore potential associations between cyclin E deregulation and inactivation of the p53 tumor suppressor gene in human breast cancer, we investigated the immunohistochemical expression of cyclin E in paraffin embedded breast cancers from 270 women with known p53 status by cDNA based sequencing of the p53 gene. The breast cancers were divided into three subgroups according to the percentage of cyclin E-positive cells. One hundred and seventy-one patients (63%) had low cyclin E, 72 (27%) medium and 27 (10%) had high cyclin E content. Fifty-six percent (15/27) of the breast cancers with high cyclin E had p53 gene mutations, compared with 14% (24/171) of those with low cyclin E content (P < 0.0001). In p53 mutated breast cancers high cyclin E content was associated with insertions, deletions and nonsense point mutations in the p53 tumor suppressor gene, whereas low cyclin E was linked to p53 missense point mutations. We also observed statistically significant associations between a high cyclin E content and aneuploidy, high S phase, larger tumor size, estrogen receptor negativity, presence of axillary node metastases and high tumor grade. High cyclin E content was associated with poor overall survival in univariate and multivariate analysis (hazard ratio 2.4, 95% confidence interval 1.3–4.5). In summary, our findings demonstrate that overexpression of cyclin E is associated with an aggressive tumor phenotype and specific types of p53 mutations.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
X. Zheng, X.-M. Rao, J. G. Gomez-Gutierrez, H. Hao, K. M. McMasters, and H. S. Zhou
Adenovirus E1B55K Region Is Required To Enhance Cyclin E Expression for Efficient Viral DNA Replication
J. Virol., April 1, 2008; 82(7): 3415 - 3427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Akli, C. S. Van Pelt, T. Bui, A. S. Multani, S. Chang, D. Johnson, S. Tucker, and K. Keyomarsi
Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway
Cancer Res., August 1, 2007; 67(15): 7212 - 7222.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Tort, J. Bartkova, M. Sehested, T. Orntoft, J. Lukas, and J. Bartek
Retinoblastoma Pathway Defects Show Differential Ability to Activate the Constitutive DNA Damage Response in Human Tumorigenesis
Cancer Res., November 1, 2006; 66(21): 10258 - 10263.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. V. Ivshina, J. George, O. Senko, B. Mow, T. C. Putti, J. Smeds, T. Lindahl, Y. Pawitan, P. Hall, H. Nordgren, et al.
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer
Cancer Res., November 1, 2006; 66(21): 10292 - 10301.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
P. Potemski, E. Pluciennik, A. K. Bednarek, R. Kusinska, D. Jesionek-Kupnicka, G. Pasz-Walczak, C. Watala, and R. Kordek
Cyclin E Expression in Operable Breast Cancer Quantified Using Real-Time RT-PCR: A Comparative Study with Immunostaining
Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Olivier, A. Langerod, P. Carrieri, J. Bergh, S. Klaar, J. Eyfjord, C. Theillet, C. Rodriguez, R. Lidereau, I. Bieche, et al.
The Clinical Value of Somatic TP53 Gene Mutations in 1,794 Patients with Breast Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1157 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Ann. Onc., November 1, 2005; 16(11): 1723 - 1739.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.